Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets

Jasdip S. Koner, Ali R. Rajabi-Siahboomi, Shahrzad Missaghi, Daniel Kirby, Yvonne Perrie, Jiteen Ahmed, Afzal R. Mohammed

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard United States Pharmacopeia (USP) test for disintegration of immediate release tablets, which requires a large volume along with repeated submergence of the dosage form within the disintegration medium. The aim of this study was to develop an in vivo relevant ODT disintegration test that mimicked the environment of the oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity that represent the conditions of the mouth. The results showed that the newly developed Aston test was able to differentiate between different ODTs with small disintegration time windows, as well as between immediate release tablets and ODTs. The Aston test provided higher correlations between ODT properties and disintegration time compared to the USP test method and most significantly, resulted in a linear in vitro/in vivo correlation (IVIVC) (R2 value of 0.98) compared with a "hockey stick" profile of the USP test. This study therefore concluded that the newly developed Aston test is an accurate, repeatable, relevant and robust test method for assessing ODT disintegration time which will provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic ODT testing regime.

Original languageEnglish
Article number12467
Number of pages9
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 28 Aug 2019

Fingerprint

Tablets
Mouth
Hockey
Pharmacopoeias
Dosage Forms
Drug Industry
Humidity
Temperature

Keywords

  • orally disintegrating tablets (ODT)
  • oral dosage forms
  • disintegration tests
  • drug administration

Cite this

Koner, Jasdip S. ; Rajabi-Siahboomi, Ali R. ; Missaghi, Shahrzad ; Kirby, Daniel ; Perrie, Yvonne ; Ahmed, Jiteen ; Mohammed, Afzal R. / Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{b9a7ac40897745e095bb464219362a71,
title = "Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets",
abstract = "Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard United States Pharmacopeia (USP) test for disintegration of immediate release tablets, which requires a large volume along with repeated submergence of the dosage form within the disintegration medium. The aim of this study was to develop an in vivo relevant ODT disintegration test that mimicked the environment of the oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity that represent the conditions of the mouth. The results showed that the newly developed Aston test was able to differentiate between different ODTs with small disintegration time windows, as well as between immediate release tablets and ODTs. The Aston test provided higher correlations between ODT properties and disintegration time compared to the USP test method and most significantly, resulted in a linear in vitro/in vivo correlation (IVIVC) (R2 value of 0.98) compared with a {"}hockey stick{"} profile of the USP test. This study therefore concluded that the newly developed Aston test is an accurate, repeatable, relevant and robust test method for assessing ODT disintegration time which will provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic ODT testing regime.",
keywords = "orally disintegrating tablets (ODT), oral dosage forms, disintegration tests, drug administration",
author = "Koner, {Jasdip S.} and Rajabi-Siahboomi, {Ali R.} and Shahrzad Missaghi and Daniel Kirby and Yvonne Perrie and Jiteen Ahmed and Mohammed, {Afzal R.}",
year = "2019",
month = "8",
day = "28",
doi = "10.1038/s41598-019-48859-x",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
number = "1",

}

Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets. / Koner, Jasdip S.; Rajabi-Siahboomi, Ali R.; Missaghi, Shahrzad; Kirby, Daniel; Perrie, Yvonne; Ahmed, Jiteen; Mohammed, Afzal R.

In: Scientific Reports, Vol. 9, No. 1, 12467, 28.08.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets

AU - Koner, Jasdip S.

AU - Rajabi-Siahboomi, Ali R.

AU - Missaghi, Shahrzad

AU - Kirby, Daniel

AU - Perrie, Yvonne

AU - Ahmed, Jiteen

AU - Mohammed, Afzal R.

PY - 2019/8/28

Y1 - 2019/8/28

N2 - Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard United States Pharmacopeia (USP) test for disintegration of immediate release tablets, which requires a large volume along with repeated submergence of the dosage form within the disintegration medium. The aim of this study was to develop an in vivo relevant ODT disintegration test that mimicked the environment of the oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity that represent the conditions of the mouth. The results showed that the newly developed Aston test was able to differentiate between different ODTs with small disintegration time windows, as well as between immediate release tablets and ODTs. The Aston test provided higher correlations between ODT properties and disintegration time compared to the USP test method and most significantly, resulted in a linear in vitro/in vivo correlation (IVIVC) (R2 value of 0.98) compared with a "hockey stick" profile of the USP test. This study therefore concluded that the newly developed Aston test is an accurate, repeatable, relevant and robust test method for assessing ODT disintegration time which will provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic ODT testing regime.

AB - Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard United States Pharmacopeia (USP) test for disintegration of immediate release tablets, which requires a large volume along with repeated submergence of the dosage form within the disintegration medium. The aim of this study was to develop an in vivo relevant ODT disintegration test that mimicked the environment of the oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity that represent the conditions of the mouth. The results showed that the newly developed Aston test was able to differentiate between different ODTs with small disintegration time windows, as well as between immediate release tablets and ODTs. The Aston test provided higher correlations between ODT properties and disintegration time compared to the USP test method and most significantly, resulted in a linear in vitro/in vivo correlation (IVIVC) (R2 value of 0.98) compared with a "hockey stick" profile of the USP test. This study therefore concluded that the newly developed Aston test is an accurate, repeatable, relevant and robust test method for assessing ODT disintegration time which will provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic ODT testing regime.

KW - orally disintegrating tablets (ODT)

KW - oral dosage forms

KW - disintegration tests

KW - drug administration

U2 - 10.1038/s41598-019-48859-x

DO - 10.1038/s41598-019-48859-x

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 12467

ER -